Related Experiment Video
Updated: Aug 26, 2025
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.3K
Treatment endpoints for chronic hepatitis D.
Olga Metin1, Müjdat Zeybel2, Cihan Yurdaydin2
1Department of Gastroenterology, Prof. Cemil Taşçioğlu City Hospital, Istanbul, Turkey.
Summary
New treatments for chronic hepatitis D (CHD) are emerging. This review discusses appropriate treatment endpoints for CHD, drawing parallels from chronic hepatitis B (CHB) studies.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis D (CHD) management is advancing with new therapies.
- Bulevirtide, a novel virus entry inhibitor, has conditional approval for compensated CHD.
- Several Phase 3 trials are underway for additional CHD treatments.
Purpose of the Study:
- To provide a perspective on defining treatment endpoints for CHD.
- To adapt existing surrogate markers from chronic hepatitis B (CHB) and C (CHC) studies for CHD.
- To propose CHD treatment endpoint suggestions considering finite vs. prolonged treatment durations and novel compound characteristics.
Main Methods:
- Literature review and synthesis of existing data.
- Comparative analysis of treatment endpoints in CHB and CHC.
- Extrapolation and adaptation of CHB study guidance for CHD.
Main Results:
- Established surrogate markers for CHB and CHC efficacy exist.
- Specific surrogate markers for CHD treatment efficacy are not yet well-defined.
- The review proposes tailored endpoint suggestions based on treatment duration and drug properties.
Conclusions:
- Defining clear treatment endpoints is crucial for evaluating new CHD therapies.
- Adaptation from CHB models, with modifications, offers a framework for CHD endpoints.
- Further research and consensus are needed to finalize CHD-specific treatment endpoints.
